Related Experiment Video
Updated: May 17, 2026
12:24
Murine Model of CD40-activation of B cells
Published on: March 5, 2010
Targeting CD30 in anaplastic large cell lymphoma.
1Fox Chase Cancer Center, Philadelphia, PA, USA.
Current Hematologic Malignancy Reports
|October 16, 2012
Summary
Anaplastic large cell lymphoma (ALCL) requires new treatments as patients often relapse after standard chemotherapy. This review explores novel CD30-targeting strategies for managing this challenging hematologic malignancy.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Anaplastic large cell lymphoma (ALCL) is a CD30-positive lymphoid neoplasm.
- Current frontline therapy involves anthracycline-based chemotherapy (e.g., CHOP), with significant relapse rates.
- ALK-negative and high-risk ALK-positive ALCL patients have a poor prognosis, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review emerging therapeutic strategies targeting CD30 in ALCL.
- To discuss the potential of various CD30-directed agents in overcoming treatment resistance and improving outcomes.
Main Methods:
- Literature review of current and investigational therapies for ALCL.
- Analysis of different approaches to targeting the CD30 antigen.
Main Results:
- Standard chemotherapy shows limited long-term efficacy in a subset of ALCL patients.
- Numerous CD30-targeting strategies are under investigation, including antibodies, conjugates, and cellular therapies.
Conclusions:
- Targeting CD30 offers promising avenues for improving ALCL treatment outcomes.
- Further research into these novel agents is crucial for managing relapsed and refractory disease.
